Treatment of the Dental Patient with Bleeding Dyscrasias

Halpern, L.; Adams, David R.; Clarkson, Earl

doi:10.1016/j.cden.2019.12.010

Cited by 4 publications

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Незважаючи на низку заходів щодо подолання стоматологічних кровотеч, відкритим залишається питання зупинки первинних та вторинних кровотеч різного ґенезу через ускладнення на фоні супутніх захворювань та паралельну фармакотерапію (здебільшого прийом антикоагулянтів). Цю проблему у своїх працях висвітлюють Леслі Р. Халперн, Девід Р. Адамс, Ерл Кларксон [8], Шайба Сандху, Алессандро Вілла [9], Мохаммед АльШиф, Дженні Грей, Абдул Салам Аль-Шаммарі [10], Озге Доганай, Белір Аталай [11], Райан Т. Рубіно, Дольф Р. Доусон, Річард Дж. Крісціо, Моханад Аль-Саббаг [12], М. Сюзен, Т. Девелі, С. Учан [13], Аманда Леал Роча, Сицилія Резенде Олівейра, Алессандра Фігейредо Соуза, Деніз Вієйра Травассос, Лукас Гімарайнш Абреу, Даніель Діас Рібейро, Тарсілія Апаресіда Сілва [14], А. Окерман, М. Борнштейн, Ю. Ю. Леунг, С. К. Лі, К. Політіс, Р. Джейкобс [15].…”

unclassified

The marketing study of the pharmaceutical market of Ukraine in the segment of antihemorrhagic agents to stop dental bleeding

Laba¹,

Azarenko²,

Євтушенко³

2021

Soc. pharm. health care

View full text Add to dashboard Cite

Aim. To conduct the marketing research of the Ukrainian market in the segment of antihemorrhagic agents used in dentistry.Materials and methods. The study was performed using the structural analysis, logical and graphical methods, marketing analysis methods.Results. The state of the Ukrainian market of drugs of this group has been determined. The market structure has been revealed in the number of names, brands, in forms of production, manufacturers, composition. Despite the sufficient number of registered drugs at the market (26 positions), a rather small arsenal of active substances (4) and dosage forms (3) can be observed. The market is characterized by a limited amount of drugs with a certain pharmacodynamics combining a rapid hemostatic effect, safety in use, the ability to suppress bacterial flora, and without the effect on healthy tissues. However, a positive moment should be noted: by the structure of manufacturer countries the market remains domestic (60 : 40).Conclusions. The Ukrainian pharmaceutical market is characterized by a sufficient assortment of hemostatic agents, but the use of these drugs in dentistry has its limitations. Dental doctors have certain problems with the occurrence of capillary bleeding and require a sufficient amount of effective and fastacting drugs for local application. Therefore, the search and creation of new drugs with a similar action at this stage remains a relevant scientific issue.

show abstract

unclassified

The marketing study of the pharmaceutical market of Ukraine in the segment of antihemorrhagic agents to stop dental bleeding

Laba¹,

Azarenko²,

Євтушенко³

2021

Soc. pharm. health care

View full text Add to dashboard Cite

show abstract

Haemophilia

2022

A Practical Approach to Special Care in Dentistry

View full text Add to dashboard Cite

Post‐procedural bleeding rate and haemostatic treatment use for dental procedures before and after the implementation of a standardized protocol for people with inherited bleeding disorders

Champagne

Bourassa

Desjardins³

et al. 2022

Haemophilia

View full text Add to dashboard Cite

Introduction Persons with inherited bleeding disorders are at a substantial risk of bleeding following dental procedures. Aim To compare the outcomes and use of haemostatic treatment pre‐ and post‐implementation of a standardized protocol for dental procedures at a Hemophilia Treatment Centre. Methods We conducted a retrospective cohort study of outpatient and inpatient dental procedures and maxillofacial surgeries sustained by people with bleeding disorders treated at a comprehensive Hemophilia Treatment Centre (2013‐2020), comparing patients’ outcomes before and after the introduction of the protocol in 2018. The protocol, built using a multidisciplinary approach, suggested haemostatic treatment based on the invasiveness of the dental procedure and the proposed anaesthesia. Our primary outcome was the rate of procedural bleeding leading to medical or dental reintervention within 10 days. Secondary outcomes included the use of systemic haemostatic treatment and treatment‐related adverse effects. Results Overall, 137 dental procedures in 95 patients (median age: 29 years; 78% males; 74% haemophilia, 14% von Willebrand disease, 12% other disorders) were included. Seventeen procedural bleedings were reported (12.4%). Procedural bleeding occurred in 14.8% and 8.9% of patients in the control and intervention groups (p = .304). No major bleeding occurred. Tranexamic acid was used more consistently after protocol implementation (72.8% vs. 89.3%, p = .019), while factor concentrates use decreased (65.4% vs. 44.6%, p = .016), and desmopressin use remained constant (46.4% vs. 32.1%, p = .100). No treatment‐related adverse effects were reported. Conclusion The use of a standardized protocol increased the use of tranexamic acid, with a nonstatistically significant reduction in procedural bleeding rate.

show abstract

Treatment of the Dental Patient with Bleeding Dyscrasias

Cited by 4 publications

References 47 publications

The marketing study of the pharmaceutical market of Ukraine in the segment of antihemorrhagic agents to stop dental bleeding

The marketing study of the pharmaceutical market of Ukraine in the segment of antihemorrhagic agents to stop dental bleeding

Haemophilia

Post‐procedural bleeding rate and haemostatic treatment use for dental procedures before and after the implementation of a standardized protocol for people with inherited bleeding disorders

Contact Info

Product

Resources

About